Importantly, GGSI-mediated activation of the UPR pathway in MM cells is recapitulated by a GGTI-2, indicating disruption of Rab geranylgeranylation is the mechanism responsible for the observed cytotoxic effects of GGSI treatment [23]. The gene discussed is AGFG1; the disease is Miyoshi myopathy.